Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:53:36 EDT Sat 27 Jun 2026
Enter Symbol
or Name
USA
CA



Z:NNVC - NANOVIRICIDES INC - http://www.nanoviricides.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NNVC - Z0.21.21·1.480.11.34+0.021.5184.72224711.28  1.34  1.272.2299  0.8519:33:50Jun 2215 min RT 2¢

Recent Trades - Last 10 of 471
Time ETExPriceChangeVolume
19:33:50Z1.3550.055100
19:28:09Z1.360.0675
18:39:43Z1.320.021
18:33:49Z1.320.02300
18:14:31Z1.3440.044100
17:59:54Z1.35850.0585385
17:55:20Z1.360.0612
17:54:48Z1.35480.0548300
17:53:16Z1.320.0240
17:17:56Z1.340.04420

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-06-22 09:30U:NNVCNews ReleaseNanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
2026-06-15 08:30U:NNVCNews ReleaseAs the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
2026-06-08 08:30U:NNVCNews ReleaseAs the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
2026-05-26 08:30U:NNVCNews ReleaseIn the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
2026-05-18 23:55U:NNVCNews ReleaseNanoViricides Announces Closing of ~$2 Million Registered Direct Offering
2026-05-18 08:30U:NNVCNews ReleaseEbola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
2026-05-15 08:35U:NNVCNews ReleaseNanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
2026-05-15 08:00U:NNVCNews ReleaseNanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II
2026-05-11 08:30U:NNVCNews ReleaseRecent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
2026-05-06 15:38U:NNVCNews ReleaseNanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference
2026-05-04 08:30U:NNVCNews ReleaseNV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
2026-04-21 08:30U:NNVCNews ReleaseDeadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
2026-04-07 08:30U:NNVCNews ReleaseMeasles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
2026-04-01 08:30U:NNVCNews ReleasePhase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
2026-03-11 08:30U:NNVCNews ReleaseNanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
2026-02-12 08:30U:NNVCNews ReleaseMPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
2026-02-10 08:30U:NNVCNews ReleaseMeasles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
2026-02-02 08:30U:NNVCNews ReleaseNanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres
2026-01-13 08:30U:NNVCNews ReleaseNanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2
2025-12-01 08:30U:NNVCNews ReleaseNanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles